What is the proper usage and management of Quillipta (inhalation powder) for respiratory conditions like asthma or Chronic Obstructive Pulmonary Disease (COPD)?

Quillipta Information Not Available

I cannot provide specific guidance on "Quillipta" as an inhalation powder because this medication name does not appear in any of the provided evidence, current medical literature, or FDA-approved drug databases.

Possible Explanations

This may be a misspelling or confusion with existing medications:

• Breo Ellipta (fluticasone furoate/vilanterol) - A once-daily ICS/LABA combination inhaler approved for both COPD and asthma, delivered via the Ellipta device 1, 2, 3
• Anoro Ellipta - A LAMA/LABA combination for COPD
• Trelegy Ellipta - A triple therapy (ICS/LAMA/LABA) for COPD

If You Meant Breo Ellipta (FF/VI)

For COPD patients with FEV1 <60% predicted and respiratory symptoms, use fluticasone furoate/vilanterol 100/25 mcg once daily in the morning 4, 2, 3.

COPD Management Algorithm

• Symptomatic patients with FEV1 ≥60% predicted: Start with monotherapy using either long-acting anticholinergics or long-acting β-agonists 4

• Symptomatic patients with FEV1 <60% predicted:

  • Begin with monotherapy (long-acting anticholinergic OR long-acting β-agonist) 4
  • Consider combination therapy (ICS/LABA like FF/VI) for patients with frequent exacerbations or those not adequately controlled on monotherapy 4, 3

• FF/VI provides sustained 24-hour bronchodilation with once-daily dosing, improving FEV1 by 220-236 mL compared to placebo 2

Asthma Use

• For persistent asthma requiring ICS/LABA therapy, FF/VI 100/25 mcg once daily improves lung function and reduces exacerbation frequency 1

Critical Action Required

Verify the exact medication name with the prescriber or pharmacist immediately - prescribing or dispensing an unidentified medication poses serious patient safety risks.